Changing
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer
BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction
Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling
Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial
Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes
Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
Navigating Challenges and Opportunities in the 2024 Life Sciences Industry Outlook
Life Sciences Industry, 2024 Outlook, Biotechnology, Medical Devices, Artificial Intelligence, Drug Pricing, Regulatory Changes, Supply Chain Security, Talent Shortage
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.